A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda

被引：0
作者：
Solomon J. Lubinga
Byamah B. Mutamba
Angelo Nganizi
Joseph B. Babigumira
机构：
[1] University of Washington,Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy
[2] University of Washington,Global Medicines Program, Department of Global Health
[3] Butabika National Referral Hospital for Mental,undefined
[4] Neurological and Substance Abuse Disorders,undefined
[5] Kadic Hospital,undefined
来源：
Applied Health Economics and Health Policy | 2015年 / 13卷
关键词：
Schizophrenia; Haloperidol; Risperidone; Olanzapine; Quetiapine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：493 / 506
页数：13
相关论文
共 50 条
  • [41] Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia
    Rosenheck, R
    Cramer, J
    Xu, WC
    Grabowski, J
    Douyon, R
    Thomas, J
    Henderson, W
    Charney, D
    HEALTH SERVICES RESEARCH, 1998, 33 (05) : 1237 - 1261
  • [42] Cost-effectiveness analysis of ziprasidone versus haloperidol in sequential intramuscular/oral treatment of exacerbation of schizophrenia: Economic subanalysis of the ZIMO trial
    Cañas F.
    Pérez-Solá V.
    Díaz S.
    Rejas J.
    Clinical Drug Investigation, 2007, 27 (9) : 633 - 645
  • [43] Updating and Confirming an Industry-Sponsored Pharmacoeconomic Model: Comparing Two Antipsychotics in the Treatment of Schizophrenia
    Graham, Christopher N.
    Mauskopf, Josephine A.
    Lawson, Anthony H.
    Ascher-Svanum, Haya
    Bruhn, David
    VALUE IN HEALTH, 2012, 15 (01) : 55 - 64
  • [44] Cost-effectiveness of olanzapine versus haloperidol in the treatment of schizophrenic patients in Spain
    Sacristan, JA
    Gomez, JC
    SalvadorCarulla, L
    ACTAS LUSO-ESPANOLAS DE NEUROLOGIA PSIQUIATRIA Y CIENCIAS AFINES, 1997, 25 (04): : 225 - 234
  • [45] Cost of antipsychotic polypharmacy in the treatment of schizophrenia
    Baojin Zhu
    Haya Ascher-Svanum
    Douglas E Faries
    Christoph U Correll
    John M Kane
    BMC Psychiatry, 8
  • [46] Effectiveness of maintenance treatments with atypical and typical antipsychotics in stable schizophrenia with early stage: 1-year naturalistic study
    Guo, Xiaofeng
    Fang, Maosheng
    Zhai, Jinguo
    Wang, Bo
    Wang, Chuanyue
    Hu, Bin
    Sun, Xueli
    Lv, Luxian
    Lu, Zheng
    Ma, Cui
    Guo, Tiansheng
    Xie, Shiping
    Twamley, Elizabeth W.
    Jin, Hua
    Zhao, Jingping
    PSYCHOPHARMACOLOGY, 2011, 216 (04) : 475 - 484
  • [47] Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia
    Haya Ascher-Svanum
    Baojin Zhu
    Douglas Faries
    Ron Landbloom
    Marvin Swartz
    Jeff Swanson
    BMC Psychiatry, 6
  • [48] Role of Newer Atypical Antipsychotics in the Management of Treatment-Resistant Schizophrenia
    Robin A. Emsley
    CNS Drugs, 2000, 13 : 409 - 420
  • [49] Effectiveness of Switching to Aripiprazole From Atypical Antipsychotics in Patients With Schizophrenia
    Kim, Sung-Wan
    Shin, Il-Seon
    Kim, Jae-Min
    Lee, Jeong-Hoon
    Lee, Yo-Han
    Yang, Su-Jin
    Yoon, Jin-Sang
    CLINICAL NEUROPHARMACOLOGY, 2009, 32 (05) : 243 - 249
  • [50] Cost-effectiveness analysis of interventions to achieve universal health coverage for schizophrenia in Mexico
    Cabello-Rangel, Hector
    Diaz-Castro, Lina
    Pineda-Antunez, Carlos
    SALUD MENTAL, 2020, 43 (02) : 65 - 71
12345